Cancer metastasis

November 7, 2019

Treating advanced cancers resistant to Paclitaxel/Topotecan/Temozolomide: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancers and in other advanced metastatic cancers resistant to Paclitaxel/Topotecan/Temozolomide: A pharmaceutical mixture encompassing Veliparib (ABT-888) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2,  p53, and TA-p73/p63, INK4a and others, decreases PP2A expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Paclitaxel/Topotecan/Temozolomide, and stalls advanced ovarian cancers  progression, and prolongs survival, via up-regulation of its target gene, 7/November/2019, 11.59 pm

Introduction: What they say A study from the Department of Gynecologic Oncology and Reproductive Medicine,  University of Texas M.D. Anderson Cancer Center, 1155 Pressler Dr., Houston, TX 77030, […]
October 21, 2019

Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2,  p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 21/October/2019, 10.31 pm

Introduction: What they say A study from the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, […]
September 19, 2019

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib,  Fulvestrant and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1 and CADM1/2,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer  progression, via up-regulation of its target gene, 19/September/2019, 10.29 pm

Introduction: What they say A study from Institute of Cancer Research and Royal Marsden Hospital, London, David Geffen School of Medicine at University of California, Los Angeles, Santa […]
August 30, 2019

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in relapsed chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Acalabrutinib, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PPP2R2A, HDAC8,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 30/August/2019, 10.22 pm

Introduction: What they say A study from the the Division of Hematology, Department of Internal Medicine, Ohio State University, and the Department of Veterinary Biosciences, College […]